Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure

BACKGROUND: Despite its cardiotoxicity doxorubicin is widely used for the treatment of paediatric malignancies. Current treatment regimens appear to be suboptimal as treatment strategies vary and do not follow a clear pharmacological rationale. Standardisation of dosing strategies in particular for...

Descripción completa

Detalles Bibliográficos
Autores principales: Siebel, Christian, Würthwein, Gudrun, Lanvers-Kaminsky, Claudia, André, Nicolas, Berthold, Frank, Castelli, Ilaria, Chastagner, Pascal, Doz, François, English, Martin, Escherich, Gabriele, Frühwald, Michael C., Graf, Norbert, Groll, Andreas H., Ruggiero, Antonio, Hempel, Georg, Boos, Joachim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254632/
https://www.ncbi.nlm.nih.gov/pubmed/32466789
http://dx.doi.org/10.1186/s40360-020-00417-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254632/
https://www.ncbi.nlm.nih.gov/pubmed/32466789
http://dx.doi.org/10.1186/s40360-020-00417-2

Ejemplares similares